Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population.

IF 0.9 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Indian journal of public health Pub Date : 2025-01-01 Epub Date: 2025-03-21 DOI:10.4103/ijph.ijph_505_23

Sukhpal Kaur, Latika Rohilla, Choro Athiphro Kayina, Jasvir Kaur, Gurpreet Kaur, Anjani Walia, Pramod Kumar, Ajay Singh, Sushma Saini, Shiv Lal Soni, Pankaj Malhotra

{"title":"Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population.","authors":"Sukhpal Kaur, Latika Rohilla, Choro Athiphro Kayina, Jasvir Kaur, Gurpreet Kaur, Anjani Walia, Pramod Kumar, Ajay Singh, Sushma Saini, Shiv Lal Soni, Pankaj Malhotra","doi":"10.4103/ijph.ijph_505_23","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 is declared a global pandemic by the WHO; vaccines were the need of the hour to reduce mortality and return to some form of normal life. The Indian government provides two vaccines as per the program; ChAdOx1 nCoV-19 and BBV152; Bharat Biotech COVID-19 vaccine. However, vaccine hesitancy is a major public health concern.Objective: To evaluate the adverse events following immunization (AEFIs) after COVID-19 vaccination. The safety profile of ChAdOx1 nCoV-19 and BBV152 vaccine was also studied.Materials and methods: This was a large-scale, cross-sectional survey. Beneficiaries who had their vaccination in the past 2 weeks were sent an online survey performa regarding AEFIs after COVID-19 vaccine.Results: Out of 2311 participants, 58% received ChAdOx1-nCoV-19 and 42% received BBV152 COVID-19 vaccine, with the mean ± standard deviation age (years) of 36.3 ± 14.5 and 16.9 ± 4.07, respectively. The previous history of COVID-19 infection was reported in 7% of the participants. In the ChAdOx1-nCoV-19 group, 85.3% participants reported at least one adverse reaction, with pain at site being the most common, followed by fever, fatigue, and feeling of unwellness. In the BBV152 group, 17% reported adverse reaction, with pain site being the most common, followed by tenderness, fatigue, and feeling of unwellness. In the BBV152 group, a significant positive association was observed between AEFIs and age. In the ChAdOx1-nCoV-19 group, age was marginally associated with AEFIs. AEFIs were more after first dose (121 vs. 43, P < 0.001, adjusted odds ratio (OR) =3.39 [95% confidence interval [CI]: 2.24-5.11], P < 0.001) among elderly (adjusted OR = 0.60, 95% CI: 0.36-0.99, P = 0.047) and women (721 vs. 423, P = 0.001, adjusted OR = 1.68 [95% CI: 1.24-2.29], P = 0.001).Conclusion: Our study observed that both ChAdOx1 nCoV-19 and BBV152 have a favorable safety profile without serious AEFIs in any of the beneficiaries.","PeriodicalId":13298,"journal":{"name":"Indian journal of public health","volume":"69 1","pages":"27-32"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of public health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijph.ijph_505_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: COVID-19 is declared a global pandemic by the WHO; vaccines were the need of the hour to reduce mortality and return to some form of normal life. The Indian government provides two vaccines as per the program; ChAdOx1 nCoV-19 and BBV152; Bharat Biotech COVID-19 vaccine. However, vaccine hesitancy is a major public health concern.

Objective: To evaluate the adverse events following immunization (AEFIs) after COVID-19 vaccination. The safety profile of ChAdOx1 nCoV-19 and BBV152 vaccine was also studied.

Materials and methods: This was a large-scale, cross-sectional survey. Beneficiaries who had their vaccination in the past 2 weeks were sent an online survey performa regarding AEFIs after COVID-19 vaccine.

Results: Out of 2311 participants, 58% received ChAdOx1-nCoV-19 and 42% received BBV152 COVID-19 vaccine, with the mean ± standard deviation age (years) of 36.3 ± 14.5 and 16.9 ± 4.07, respectively. The previous history of COVID-19 infection was reported in 7% of the participants. In the ChAdOx1-nCoV-19 group, 85.3% participants reported at least one adverse reaction, with pain at site being the most common, followed by fever, fatigue, and feeling of unwellness. In the BBV152 group, 17% reported adverse reaction, with pain site being the most common, followed by tenderness, fatigue, and feeling of unwellness. In the BBV152 group, a significant positive association was observed between AEFIs and age. In the ChAdOx1-nCoV-19 group, age was marginally associated with AEFIs. AEFIs were more after first dose (121 vs. 43, P < 0.001, adjusted odds ratio (OR) =3.39 [95% confidence interval [CI]: 2.24-5.11], P < 0.001) among elderly (adjusted OR = 0.60, 95% CI: 0.36-0.99, P = 0.047) and women (721 vs. 423, P = 0.001, adjusted OR = 1.68 [95% CI: 1.24-2.29], P = 0.001).

Conclusion: Our study observed that both ChAdOx1 nCoV-19 and BBV152 have a favorable safety profile without serious AEFIs in any of the beneficiaries.

查看原文本刊更多论文

ChAdOx1重组nCoV-19冠状病毒疫苗（Covishield）与BBV152的比较巴拉特生物技术COVID-19疫苗（Covaxin）用于COVID-19：印度人口接种疫苗后不良事件的报告。

背景：世卫组织宣布COVID-19为全球大流行；疫苗是降低死亡率和恢复某种形式的正常生活的迫切需要。印度政府根据该计划提供两种疫苗；ChAdOx1 nCoV-19和BBV152；巴拉特生物技术公司的COVID-19疫苗。然而，疫苗犹豫是一个主要的公共卫生问题。目的：评价COVID-19疫苗接种后免疫不良事件（AEFIs）。研究了ChAdOx1 nCoV-19和BBV152疫苗的安全性。材料和方法：这是一项大规模的横断面调查。在过去两周内接种疫苗的受益人收到了一份关于COVID-19疫苗接种后aefi的在线调查。结果：2311名参与者中，58%接种了ChAdOx1-nCoV-19疫苗，42%接种了BBV152 COVID-19疫苗，平均±标准差年龄（岁）分别为36.3±14.5和16.9±4.07。7%的参与者报告了之前的COVID-19感染史。在ChAdOx1-nCoV-19组中，85.3%的参与者报告了至少一种不良反应，其中最常见的是部位疼痛，其次是发烧、疲劳和不适感。在BBV152组中，17%的人报告了不良反应，其中疼痛部位最常见，其次是压痛、疲劳和不健康的感觉。在BBV152组中，观察到aefi与年龄之间存在显著的正相关。在ChAdOx1-nCoV-19组中，年龄与aefi轻微相关。老年人（调整OR = 0.60, 95% CI: 0.36-0.99, P = 0.047）和女性（721比423，P = 0.001，调整OR = 1.68 [95% CI: 1.24-2.29], P = 0.001）首次给药后aefi更多（121比43，P < 0.001，调整OR =3.39[95%可信区间[CI]: 2.24-5.11], P < 0.001）。结论：我们的研究发现，ChAdOx1 nCoV-19和BBV152均具有良好的安全性，在任何受益人中均未出现严重的急性脑损伤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian journal of public health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

2.40

自引率

0.00%

发文量

审稿时长

21 weeks

期刊介绍： Indian Journal of Public Health is a peer-reviewed international journal published Quarterly by the Indian Public Health Association. It is indexed / abstracted by the major international indexing systems like Index Medicus/MEDLINE, SCOPUS, PUBMED, etc. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles. The Indian Journal of Public Health publishes articles of authors from India and abroad with special emphasis on original research findings that are relevant for developing country perspectives including India. The journal considers publication of articles as original article, review article, special article, brief research article, CME / Education forum, commentary, letters to editor, case series reports, etc. The journal covers population based studies, impact assessment, monitoring and evaluation, systematic review, meta-analysis, clinic-social studies etc., related to any domain and discipline of public health, specially relevant to national priorities, including ethical and social issues. Articles aligned with national health issues and policy implications are prefered.